GlaxoSmithKline

GSK's Menveo meningococcal vaccine in a new single-vial, fully liquid presentation receives positive European CHMP opinion. If approved, it will offer healthcare providers a non-reconstituted option for MenACWY vaccine before use, with a marketing authorisation expected by November 2024. Over 6 million doses of GSK's MenACWY vaccine have been distributed to European countries since 2017.

EMA's CHMP recommends a fully liquid Menveo (MenACWY vaccine) for invasive meningococcal disease, expected EU approval by Nov 2024. This single-vial option simplifies immunisation for children, adolescents, and adults.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

UK-based Vicebio raised $100m in Series B funding led by TCGX to advance its RSV and hMPV vaccine VXB-241 to Phase I trials, utilizing its 'molecular clamp' technology for enhanced immune response.

Landmark, a three-year research partnership involving Parkinson's UK, Imperial College London, and pharmaceutical companies, aims to sequence tissue samples from the Parkinson's UK Brain Bank to build a gene expression map, identify biomarkers, and discover new drug targets for Parkinson's disease. Funded by a £4m gift from the Gatsby charitable foundation, the project will use snRNAseq to analyze samples, producing a major dataset for global research and informing new treatments through Parkinson's Virtual Biotech.

5 in 6 Americans who tried to quit smoking in 2022 failed, highlighting ineffective treatments and lack of innovation. Despite the addiction killing 480,000 annually, no new class of drugs has been approved in nearly two decades. Drugmakers and the FDA are criticized for lackadaisical approaches and stringent approval standards, focusing more on profitable drugs for rare cancers. Advocates call for a 'Reduce to Quit' approach and more flexible FDA standards to address the public health crisis.

Citi Pharma, Pakistan's largest API producer, will export nutraceuticals to the US, expecting $3 million in export revenue with 25-30% profit margins. Nutraceuticals face less rigorous FDA regulation than pharmaceuticals, allowing for quicker market entry.

A. Lenore Ackerman discusses the potential use of oral sulopenem for uncomplicated UTIs, emphasizing its role in high-risk patients with multi-drug-resistant infections, cautioning against its broad use due to concerns over resistance development.

The global Type 1 Diabetes (T1D) market, valued at $6.5 billion in 2023, is projected to grow to $11.3 billion by 2032, driven by increasing diabetes prevalence, technological advancements, and rising healthcare expenditure. Innovations like CGM systems and artificial pancreas devices enhance patient outcomes. Insulin therapy remains central, with advancements in delivery methods and digital health integration. Regional growth is led by North America, with Asia Pacific showing rapid expansion. Challenges include treatment costs and access, with efforts underway to improve affordability and equity.

Niger launches malaria vaccine campaign in Gaya, aiming to reduce child mortality; RTS,S by GSK added to routine vaccination calendar. Expected to be 75% effective against severe malaria, with 5 million cases and over 5,000 deaths annually in Niger. Complemented by free mosquito nets and preventive medication.